UA87822C2 - Naphthylene derivatives as cytochrome p450 inhibitors - Google Patents

Naphthylene derivatives as cytochrome p450 inhibitors

Info

Publication number
UA87822C2
UA87822C2 UAA200601312A UAA200601312A UA87822C2 UA 87822 C2 UA87822 C2 UA 87822C2 UA A200601312 A UAA200601312 A UA A200601312A UA A200601312 A UAA200601312 A UA A200601312A UA 87822 C2 UA87822 C2 UA 87822C2
Authority
UA
Ukraine
Prior art keywords
cytochrome
inhibitors
treatment
naphthylene
derivatives
Prior art date
Application number
UAA200601312A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Ванесса Смит
Энтони Найгро
Марк Малвихилл
Кара Сесарио
Патришия Энн Бек
Арлиндо Лукас Кастелано
Original Assignee
Оси Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оси Фармасьютикалз, Инк. filed Critical Оси Фармасьютикалз, Инк.
Publication of UA87822C2 publication Critical patent/UA87822C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Compounds of the formula (I); and pharmaceutically acceptable salts thereof, wherein n1, n2, n3, n4, G,Q, Z, R, R, R, R, R, R, and Rare defined herein, inhibit the cytochrome P450RAI enzyme and are useful for the treatment and/or prevention of various diseases and conditions which respond to treatment by retinoids and by naturally occurring retinoic acid.(I)
UAA200601312A 2003-07-10 2004-12-07 Naphthylene derivatives as cytochrome p450 inhibitors UA87822C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48638203P 2003-07-10 2003-07-10

Publications (1)

Publication Number Publication Date
UA87822C2 true UA87822C2 (en) 2009-08-25

Family

ID=34079229

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200601312A UA87822C2 (en) 2003-07-10 2004-12-07 Naphthylene derivatives as cytochrome p450 inhibitors

Country Status (15)

Country Link
EP (1) EP1654236A1 (en)
JP (1) JP4832295B2 (en)
KR (1) KR20060052799A (en)
CN (1) CN1819996B (en)
AU (1) AU2004257257B2 (en)
BR (1) BRPI0412424A (en)
CA (1) CA2532078A1 (en)
IL (1) IL172812A0 (en)
IS (1) IS8223A (en)
MX (1) MXPA06000401A (en)
NO (1) NO20060114L (en)
RU (1) RU2363696C2 (en)
SG (1) SG144941A1 (en)
UA (1) UA87822C2 (en)
WO (1) WO2005007631A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007515433A (en) * 2003-12-17 2007-06-14 アラーガン　インコーポレイテッド Methods of treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
JP6088425B2 (en) 2010-06-01 2017-03-01 アンジオン バイオメディカ コーポレーション Cytochrome P450 inhibitors and uses thereof
KR101848077B1 (en) * 2010-11-13 2018-04-11 이노크린 파마슈티컬즈, 인크. Metalloenzyme inhibitor compounds
BR112013014484A2 (en) * 2010-12-13 2016-07-19 Viamet Pharmaceuticals Inc metalloenzyme inhibitor compounds
CN102586187A (en) * 2012-02-23 2012-07-18 深圳市中美康士生物科技有限公司 In vitro preservation method and culture medium for neutrophils
WO2014015137A2 (en) * 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
CA2957785C (en) 2014-08-11 2023-01-03 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
CN104523967B (en) * 2014-12-12 2017-08-01 扬子江药业集团北京海燕药业有限公司 A kind of Bai Ai capsules as CYP enzyme inhibitors application
CN107531631B (en) 2014-12-31 2021-09-03 安吉昂生物医药公司 Methods and agents for treating diseases
GB201602572D0 (en) * 2016-02-12 2016-03-30 Eriksson Leif And Strid Ake And Sirsjö Allan New compound and uses
WO2018065288A1 (en) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft 2-[2-phenyl-1-(sulfonyl-methyl)-vinyl]-imidazo-[4,5-b] pyridine derivatives and related compounds as pesticides in plant protection
KR102515694B1 (en) 2017-01-10 2023-03-29 바이엘 악티엔게젤샤프트 Heterocycle derivatives as pest control agents
TW201837026A (en) 2017-01-10 2018-10-16 德商拜耳廠股份有限公司 Heterocycle derivatives as pesticides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291944A (en) * 1960-05-04
NL131915C (en) * 1966-07-27
DE3508903A1 (en) * 1985-03-13 1986-09-18 Hoechst Ag, 6230 Frankfurt NEW 3-PYRIDYLMETHYLNAPHTYL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS
DE3628545A1 (en) * 1985-09-23 1987-04-23 Hoechst Ag ARYLMETHYLAZOLES AND THEIR SALTS, METHOD FOR THE PRODUCTION THEREOF, MEANS CONTAINING THEM AND THEIR USE
WO1994008973A1 (en) * 1992-10-21 1994-04-28 Sankyo Company, Limited Azole compound
JP4546589B2 (en) * 1998-04-23 2010-09-15 武田薬品工業株式会社 Naphthalene derivatives
ATE293102T1 (en) * 1998-04-23 2005-04-15 Takeda Pharmaceutical NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE
FR2796070B1 (en) * 1999-07-06 2003-02-21 Lipha BENZODIAZEPINES DERIVATIVES FOR USE IN THE TREATMENT OF DYSLIPIDEMIA, ATHEROSCLEROSIS AND DIABETES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS OF PREPARATION
PE20010781A1 (en) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd COMPOUNDS 1- (1H-IMIDAZOL-4-IL) -1- (NAFTIL-2-SUBSTITUTED) ETHANOL, ITS PRODUCTION AND USE
JP4520012B2 (en) * 1999-10-22 2010-08-04 武田薬品工業株式会社 1-Substituted-1- (1H-imidazol-4-yl) methanols

Also Published As

Publication number Publication date
CA2532078A1 (en) 2005-01-27
IS8223A (en) 2006-01-10
IL172812A0 (en) 2006-06-11
AU2004257257A1 (en) 2005-01-27
RU2363696C2 (en) 2009-08-10
CN1819996B (en) 2010-10-27
JP2007523866A (en) 2007-08-23
NO20060114L (en) 2006-02-09
WO2005007631A1 (en) 2005-01-27
JP4832295B2 (en) 2011-12-07
SG144941A1 (en) 2008-08-28
RU2006103996A (en) 2006-07-10
KR20060052799A (en) 2006-05-19
EP1654236A1 (en) 2006-05-10
BRPI0412424A (en) 2006-09-05
AU2004257257B2 (en) 2011-05-12
CN1819996A (en) 2006-08-16
MXPA06000401A (en) 2006-03-17

Similar Documents

Publication Publication Date Title
NO20060114L (en) Naphthylene derivatives as cytochrome P450 inhibitors
HK1133596A1 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
TW200728307A (en) Novel spirochromanone derivatives
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
WO2008075172A3 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
NZ598242A (en) Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
TW200612958A (en) Substituted imidazole derivatives
MXPA03006248A (en) Fumaric acid derivatives as nf-kappab inhibitors.
AU2003297291A1 (en) Substituted arylcyclopropylacetamides as glucokinase activators
BR0316583A (en) Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (parent-1)
IL179607A0 (en) Indoles useful in the treatment of inflammation
DK1753723T3 (en) Substituted quinoline derivatives as mitotic kinesin inhibitors
WO2007084728A3 (en) 2-imino-benzimidazoles
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
EP1831239B8 (en) A process for the preparation of 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bismethylene-17 alpha-pregn-4-ene-3-one-21-carboxylic acid gamma-lactone and key-intermediates for this process
NO20083708L (en) 4-Phenyl-thiazole-5-carboxylic acid and 4-phenyl-thiazole-5-carboxylmides as PLK1 inhibitors
TW200613289A (en) Prodrugs of hiv protease inhibitors
UA97256C2 (en) Substituted pyrazole and triazole compounds as ksp (kinesin spindle protein) inhibitors
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
MX2009010302A (en) Indole derivative having cpla2 inhibitory activity, use of the same and method for producing the same.
WO2009051223A1 (en) Pharmaceutical composition for treatment of cataract
WO2004012663A3 (en) Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
DE602005011267D1 (en) BENZOFURAN AND BENZOTHIOPHONE DERIVATIVES SUITABLE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES